ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

MLA

Leora Horn, et al. “ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: EXalt3.” Journal of Thoracic Oncology, vol. 15, Oct. 2020, pp. e41–42. EBSCOhost, https://doi.org/10.1016/j.jtho.2020.08.003.

APA

Leora Horn, Yunpeng Liu, G. Wu, Giovanni Selvaggi, Elena Poddubskaya, Sergey Orlov, Jianying Zhou, Li Mao, V. Oertel, Martin Reck, Irfan Cicin, Yun Fan, Ying Cheng, Tony Mok, Valeriy Breder, Ziping Wang, Chris Liang, Heather A. Wakelee, D.H. Lee, … Alberto Chiappori. (2020). ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3. Journal of Thoracic Oncology, 15, e41–e42. https://doi.org/10.1016/j.jtho.2020.08.003

Chicago

Leora Horn, Yunpeng Liu, G. Wu, Giovanni Selvaggi, Elena Poddubskaya, Sergey Orlov, Jianying Zhou, et al. 2020. “ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: EXalt3.” Journal of Thoracic Oncology 15 (October): e41–42. doi:10.1016/j.jtho.2020.08.003.